Showing 7831-7840 of 8648 results for "".
- COVID-19 Has Flipped the Physician Job Search to a Seller’s Market, Recruiters Sayhttps://modernod.com/news/covid-19-has-flipped-the-physician-job-search-to-a-sellers-market-recruiters-say/2478020/Job opportunities for doctors have dried up quite a bit in wake of the COVID-19 pandemic, at least in the short term, according to an annual report from physician search firm Merritt Hawkins, according to a FierceHealthcare
- National Glaucoma Research Foundation Survey Reveals Patients’ Experiences and Concerns During COVID-19https://modernod.com/news/national-glaucoma-research-foundation-survey-reveals-patients-experiences-and-concerns-during-covid-19/2478017/Glaucoma Research Foundation (GRF) announced results from a survey designed to explore glaucoma patients’ experiences and concerns during the COVID-19 pandemic-related shutdowns. The survey, conducted among patients in the GRF database and suppo
- Senate Democrats Demand $25 Billion for Widespread COVID-19 Vaccine Distributionhttps://modernod.com/news/senate-democrats-demand-25-billion-for-widespread-covid-19-vaccine-distribution/2478013/Senate Democrats want to pass legislation that provides $25 billion to ensure a potential COVID-19 vaccine is heavily distributed among the U.S. population, according to a FierceHealthcare
- Santen and NTC Release Results of Phase 3 Clinical Study Examining 7-Day Fixed Dose Combination of Levofloxacinhttps://modernod.com/news/santen-and-ntc-release-results-of-phase-3-clinical-study-examining-7-day-fixed-dose-combination-of-levofloxacin/2478007/Santen EMEA and NTC have announced that the results of their phase 3 clinical study, LEADER7, have been published in Eye. The study demonstrated for the first time that 7-day levofloxacin/dexamethasone eye dr
- EyePoint Pharmaceuticals Names Jay S. Duker, MD, Chief Strategic Scientific Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-names-jay-s-duker-md-chief-strategic-scientific-officer/2478005/EyePoint Pharmaceuticals announced the appointment of Jay S. Duker, MD, as Chief Strategic Scientific Officer. In this newly created role, Dr. Duker will lead the strategic advancement of our research and development efforts, beginning with our lead development candidate EYP-1901 for wet age-rela
- ImprimisRx: Clinical Study Examines Combination Prescription Eyedropshttps://modernod.com/news/imprimisrx-clinical-study-examines-combination-prescription-eyedrops/2478002/ImprimisRx announced the findings from a randomized contralateral eye study comparing patient outcomes and preferences for a combination therapy with individual eye drop medications after ocular surgery. The prospective study,
- Women in Ophthalmology (WIO) 2020 Summer Symposium Goes Virtualhttps://modernod.com/news/women-in-ophthalmology-wio-2020-summer-symposium-goes-virtual/2477999/Due to the recent rise in COVID-19 cases in Florida, Women in Ophthalmology (WIO) has decided to is move its Summer Symposium to an all-virtual platform on August 21-23, 2020. “In classic WIO fashion, we have planned an innovative meeting like no other with 24 hours of CME, scientifi
- Biogen Boosts Gene Therapy Strategy With Harvard Pact Focused on Inherited Eye Diseasehttps://modernod.com/news/biogen-boosts-gene-therapy-strategy-with-harvard-pact-focused-on-inherited-eye-disease/2477996/Mutations in more than 270 genes have been implicated in inherited eye diseases like retinitis pigmentosa. Now, Biogen has formed a research pact with Harvard’s Massachusetts Eye and Ear that’s aimed at developing a gene therapy to help some patients with these blinding diseases, according to a F
- Nicox Partner Ocumension Completes Successful Hong Kong IPOhttps://modernod.com/news/nicox-partner-ocumension-completes-successful-hong-kong-ipo/2477998/Nicox SA’s partner Ocumension Therapeutics had a successful IPO on the Hong Kong Stock Exchange and provided an update on the programs in the collaboration. Ocumension Therapeutics began trading on the Hong Kong Stock Exchange on July 10, 2020 after an IPO raising HK $1,424 (~US $184
- LumiThera Closes Series C Round of Financinghttps://modernod.com/news/lumithera-closes-series-c-round-of-financing/2477993/LumiThera announced it has completed its Series C financing. The company raised approximately $14 million to support further commercialization of its Valeda Light Delivery System for the treatment for dry age-related macular degeneration (AMD), to complete its LIGHTS